Aug 9, 2018
Eyevensys Appoints New Board Member, Gerald Cagle

Paris (France), August 9th, 2018 – Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, today announced that Gerald (Jerry) Cagle, Ph.D., former Senior Vice President and Chief Scientific Officer at Alcon Laboratories has joined its Board  of Directors.

Dr. Cagle is a highly respected pharmaceutical executive with managerial, technical and business experience spanning almost 40 years. Dr. Cagle served in key leadership roles for Alcon Laboratories Inc., including positions in clinical research, regulatory affairs, and product development. During the last 13 years at Alcon, he held the position of Senior Vice President and Chief Scientific Officer, introducing a range of new products. Dr. Cagle holds 28 issued patents in both drug and device areas and has published numerous scientific articles. More recently, he has served on the Boards of several life sciences companies.

Dr. Patricia Zilliox, CEO of Eyevensys, stated: “I am excited to welcome Dr. Cagle to our Board of Directors. His extensive wealth of product development and industry experience will be key to leverage our unique EyeCET platform. We expect Jerry’s expertise to be valuable as we further progress our lead product EYS606, currently in a Phase I/II clinical trial for the potential treatment of non-infectious uveitis (NIU).”

Dr. Gerald Cagle said: “I am delighted to join Eyevensys’ Board and look forward to working with a strong team and unlock the potential of its pioneering ocular drug delivery technology. The EyeCET technology is a very promising approach to address the deficiencies of current therapies for the treatment of a range of eye diseases. I look forward to contributing to the preclinical and clinical development efforts. ”